From pathogenesis to treatment of chronic lymphocytic leukaemia
- PMID: 19956173
- DOI: 10.1038/nrc2764
From pathogenesis to treatment of chronic lymphocytic leukaemia
Abstract
Chronic lymphocytic leukaemia (CLL) has several unique features that distinguish it from other cancers. Most CLL tumour cells are inert and arrested in G0/G1 of the cell cycle and there is only a small proliferative compartment; however, the progressive accumulation of malignant cells will ultimately lead to symptomatic disease. Pathogenic mechanisms have been elucidated that involve multiple external (for example, microenvironmental stimuli and antigenic drive) and internal (genetic and epigenetic) events that are crucial in the transformation, progression and evolution of CLL. Our growing understanding of CLL biology is allowing the translation of targets and biological classifiers into clinical practice.
Similar articles
-
New directions in the diagnosis and treatment of chronic lymphocytic leukaemia.Drugs. 2003;63(10):953-69. doi: 10.2165/00003495-200363100-00003. Drugs. 2003. PMID: 12699399 Review.
-
Microenvironmental interactions in chronic lymphocytic leukemia: hints for pathogenesis and identification of targets for rational therapy.Curr Pharm Des. 2012;18(23):3323-34. doi: 10.2174/138161212801227078. Curr Pharm Des. 2012. PMID: 22591383 Review.
-
The molecular pathogenesis of chronic lymphocytic leukaemia.Nat Rev Cancer. 2016 Mar;16(3):145-62. doi: 10.1038/nrc.2016.8. Nat Rev Cancer. 2016. PMID: 26911189 Review.
-
Chronic lymphocytic leukaemia: the nature of the leukaemic cell.Blood Rev. 1997 Sep;11(3):119-28. doi: 10.1016/s0268-960x(97)90007-2. Blood Rev. 1997. PMID: 9370043 Review.
-
Murine models for chronic lymphocytic leukaemia.Biochem Soc Trans. 2007 Nov;35(Pt 5):1009-12. doi: 10.1042/BST0351009. Biochem Soc Trans. 2007. PMID: 17956265 Review.
Cited by
-
Homeostatic chemokines guide lymphoma cells to tumor growth-promoting niches within secondary lymphoid organs.J Mol Med (Berl). 2012 Nov;90(11):1237-45. doi: 10.1007/s00109-012-0906-z. Epub 2012 May 11. J Mol Med (Berl). 2012. PMID: 22577036 Review.
-
Can prognostic factors be used to direct therapy in chronic lymphocytic leukemia?Curr Hematol Malig Rep. 2012 Mar;7(1):3-12. doi: 10.1007/s11899-011-0110-1. Curr Hematol Malig Rep. 2012. PMID: 22237849 Review.
-
Total proteome analysis identifies migration defects as a major pathogenetic factor in immunoglobulin heavy chain variable region (IGHV)-unmutated chronic lymphocytic leukemia.Mol Cell Proteomics. 2015 Apr;14(4):933-45. doi: 10.1074/mcp.M114.044479. Epub 2015 Feb 2. Mol Cell Proteomics. 2015. PMID: 25645933 Free PMC article.
-
Concurrent epigenetic silencing of wnt/β-catenin pathway inhibitor genes in B cell chronic lymphocytic leukaemia.BMC Cancer. 2012 Jun 6;12:213. doi: 10.1186/1471-2407-12-213. BMC Cancer. 2012. PMID: 22672427 Free PMC article.
-
Peptides that bind specifically to an antibody from a chronic lymphocytic leukemia clone expressing unmutated immunoglobulin variable region genes.Mol Med. 2013 Aug 28;19(1):245-52. doi: 10.2119/molmed.2013.00082. Mol Med. 2013. PMID: 23922242 Free PMC article.
References
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources